Drug Profile
GSK 2654911A
Alternative Names: GSK2654911ALatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Influenza A virus H9N2 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H9N2 subtype
Most Recent Events
- 12 Jun 2014 GlaxoSmithKline completes a phase I trial in Influenza-A virus infections in Canada and USA (NCT01659086)
- 31 Aug 2012 Phase-I clinical trials in Influenza A virus infections in Canada (IM)
- 31 Aug 2012 Phase-I clinical trials in Influenza A virus infections in USA (IM)